Compare Amylx Pharmaceuticals Inc (AMLX) vs General Motors Company (GM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs General Motors Company — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while General Motors Company trades at $77.8 (market cap $70.19B). The key difference: General Motors Company is far larger — about 35.4× Amylx Pharmaceuticals Inc's market cap, and General Motors Company pays a 0.92% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | GM | |
|---|---|---|
Market Cap | $1.98B | $70.19B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $86.38 |
52-Week Low | $7.64 | $48.89 |
Enterprise Value | $1.70B | $173.53B |
Dividend Yield | — | 0.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
General Motors (GM) trades at $77.85, up 1.57% with a bearish technical signal despite three consecutive quarterly earnings beats. The company maintains strong cash flow generation ($26.9B operating cash flow in 2025) and trades at discounted valuations (P/S 0.4, P/B 1.12). Recent news highlights GM's strategic pivot into energy and battery technology partnerships as automotive sales face industry headwinds.
GM presents a value opportunity with analyst consensus price target of $100.27 (29% upside) but faces execution risks in EV transition and margin pressure. The stock's outlook depends on Q2 earnings delivering clean cash flow and sustained margin improvement amid competitive and macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
